Reporter Staff
| This email address is being protected from spambots. You need JavaScript enabled to view it.
September 01, 2023
How did we do? Forging the Future of Patient Care
Revisiting the successes in patient care achieved together through UAB’s current strategic plan.
Published in
Campus News
September 01, 2023
How did we do? Forging the Future of Community Engagement
Revisiting the successes in community engagement achieved together through UAB’s current strategic plan.
Published in
Campus News
September 01, 2023
How did we do? Forging the Future of Research
Revisiting the research successes achieved together through UAB’s current strategic plan.
Published in
Campus News
September 01, 2023
How did we do? Forging the Future of Education
Revisiting the academic successes achieved together through UAB’s current strategic plan.
Published in
Campus News
CURB-2 is an abbreviation we use to refer to this study because there was a similar study completed and published in 2016 called CURB, which stands for Cocaine Use Reduction with Buprenorphine. The results from that study showed that using injectable naltrexone and sublingual buprenorphine was beneficial to participants on high doses of the medication. This study will give injectable naltrexone and injectable buprenorphine to make sure medication doses are consistent to confirm potential benefits.
There are no approved treatments specifically for cocaine use disorder. We are looking for adults (18-65 years of age) who are using cocaine and who are interested in reducing or stopping their use. The purpose of our study is to test a combination of two medications for 2 months as a possible treatment for cocaine use disorder.
This study includes the use of a placebo, which looks like the medication we are testing but does not include any active medicine. Study medication and assessments will be provided to participants at no cost. Participants will receive compensation for their time and efforts.
Study information will be kept strictly confidential. Your privacy is important to us.
Call us for more information at 205-996-0211 or email us at curb2study@uabmc.edu
There are no approved treatments specifically for cocaine use disorder. We are looking for adults (18-65 years of age) who are using cocaine and who are interested in reducing or stopping their use. The purpose of our study is to test a combination of two medications for 2 months as a possible treatment for cocaine use disorder.
This study includes the use of a placebo, which looks like the medication we are testing but does not include any active medicine. Study medication and assessments will be provided to participants at no cost. Participants will receive compensation for their time and efforts.
Study information will be kept strictly confidential. Your privacy is important to us.
Call us for more information at 205-996-0211 or email us at curb2study@uabmc.edu
Published in
Clinical Trials
August 28, 2023
Wellscreens appointments now available for fall — register today
The annual initiative from UAB Employee Wellness provides a free, 15-minute health screening to all benefit-eligible UAB, UAB Hospital, UAB LLC, UAB Health System/UA Health Services Foundation and Cooper Green employees. Appointments are available Sept. 25-Nov. 13.
Published in
Be Healthy
August 24, 2023
Where to buy UAB merch so you can ‘Be Seen in Green’
UAB employees and fans are encouraged to wear green each Friday to show their support for UAB Football and the Blazer community. Wondering where to get your UAB gear? Check out a list of places on campus, online and around town.
Published in
Go Blazers!
August 17, 2023
Demolition of Ice House requires temporary road closure
Beginning Aug. 19, 22nd Street South will be closed between 4th Avenue South and 5th Avenue South. See a map of the closure area and detour.
Published in
Campus News
August 14, 2023
Do you have a child aged 6 months to 18 years of age that is scheduled to receive the COVID-19 vaccine series or booster?
If so, they could be a part of a study that looks at the long-term effects of receiving the COVID-19 vaccine. Healthy children or children with conditions affecting their immune systems are eligible to enroll. Blood samples and nasal swabs will be collected every 2 months for one year. An echocardiogram and EKG will also be required at the second visit. Compensation for participation is available. To learn more, contact the UAB study team: 205-638-2629 or mlpurser@uabmc.edu
Published in
Clinical Trials
August 14, 2023
CMVibe Study: Evaluates a CMV vaccine in healthy females or males aged 9-15 years old
Congenital CMV infection is the most common infection passed from the mother to baby during pregnancy. It is also the most common non-hereditary cause of hearing loss and brain damage in children. You or your child will have 3 injections, several months apart. You will have approximately 11 clinic visits over the 18 month study period. Saliva swabs, urine, and blood samples will be required. Compensation for participation is available. To learn more, visit CMVibeTrial.com or contact the UAB study team: 205-638-2629 or mlpurser@uabmc.edu
Published in
Clinical Trials
